Pharmakologische und klinische Eigenschaften eines neuen Butyrophenon-Derivates (FR 33)

Summary

In the present investigation the pharmacological and clinical results obtained with a new butyrophenone derivative, FR-33, were compared with one another as well as with those of two known butyrophenone derivatives. The comparison revealed a distinct parallelism between the main findings from the animal experiment and the clinical activity of these substances. With all three substances, the inhibition of the amphetamine excitation and the conditioned escape response as well as the induced catalepsy run a parallel course and correlate to a certain extent with the clinically observed sedative-neuroleptic effects. FR-33 produces in man very little sedation but a pronounced autismolytic, stupor-relieving and energizing effect. This is reflected in the animal experiment in a relatively pronounced anti-emotional and activating effect. FR-33 possesses most of the properties typical of the butyrophenones. However, due to the almost complete absence of a sedative effect it occupies a special place in this series of compounds and differs therewith fundamentally from the phenothiazine derivatives. The indication for FR-33 is chiefly chronic stuporous katatonia.